关注
Rayan Sabra
Rayan Sabra
Biopharmaceutics Investigator
在 lau.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Assessment of toxic metals and phthalates in children’s toys and clays
SI Korfali, R Sabra, M Jurdi, RI Taleb
Archives of environmental contamination and toxicology 65, 368-381, 2013
792013
Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer
R Sabra, N Billa, CJ Roberts
International journal of pharmaceutics 572, 118775, 2019
722019
An augmented delivery of the anticancer agent, curcumin, to the colon
R Sabra, N Billa, CJ Roberts
Reactive and Functional Polymers 123, 54-60, 2018
552018
Prospects of curcumin nanoformulations in cancer management
H Amekyeh, E Alkhader, R Sabra, N Billa
Molecules 27 (2), 361, 2022
292022
Courier properties of modified citrus pectinate-chitosan nanoparticles in colon delivery of curcumin
R Sabra, CJ Roberts, N Billa
Colloid and Interface Science Communications 32, 100192, 2019
292019
Mechanisms and extent of enhanced passive permeation by colloidal drug particles
A Narula, R Sabra, N Li
Molecular pharmaceutics 19 (9), 3085-3099, 2022
212022
Comparisons of in Vitro Models to Evaluate the Membrane Permeability of Amorphous Drug Nanoparticles
R Sabra, A Narula, LS Taylor, N Li
Molecular pharmaceutics 19 (9), 3412-3428, 2022
92022
Gastrointestinal delivery of APIs from chitosan nanoparticles
R Sabra, N Billa
Chitin Chitosan-Physicochem. Prop. Ind. Appl, 2020
72020
Soliciting the oral route as a logical approach to managing colon cancer
R Sabra, N Billa
Frontiers in Bioengineering and Biotechnology 9, 645923, 2021
22021
A Window for Enhanced Oral Delivery of Therapeutics via Lipid Nanoparticles
H Amekyeh, R Sabra, N Billa
Drug Design, Development and Therapy, 613-630, 2024
2024
系统目前无法执行此操作,请稍后再试。
文章 1–10